Two weeks after announcing concerns about high-levels of carcinogens in popular diabetes drugs, the U.S. Food and Drug Administration announced the first voluntary recalls of this class of drugs manufactured by five companies.
The FDA found high levels of the same type of carcinogen that led to the recall of some hypertension and heartburn medications in some of the extended-release version metformin drugs that had been tested.
Johnson & Johnson will stop selling talc Baby Powder in the United States and Canada, saying demand had fallen in the wake of what the company called “misinformation” about the product’s safety amid a barrage of legal challenges.
The U.S. Food and Drug Administration is requesting makers of all versions of the heartburn drug Zantac to remove the products from the market immediately due to the presence of a probable carcinogen.
Johnson & Johnson was ordered by a New Jersey state jury to pay punitive damages of $750 million to four plaintiffs who allege that the company’s Baby Powder caused their cancer, a ruling that will be reduced to around $185 million because of state laws, according to a lawyer for the plaintiffs and J&J.
Mylan has come under fire from the U.S. Food and Drug Administration over inadequate good manufacturing practices at one of the company’s drug manufacturing facilities in India.
For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.
In the wake of the discovery that some Zantac products may contain a carcinogen contaminant due to the manufacturing process, drug store retailers removed the antacid from shelves.
The NovoTTF-100L therapy has become an FDA-approved therapy that is helping improve the lives of mesothelioma patients.
Novartis’ Sandoz division recalled one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug.